NCT04963153
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04963153
Title Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | CAN

Facility Status City State Zip Country Details
Los Angeles General Medical Center Los Angeles California 90033 United States Details
USC / Norris Comprehensive Cancer Center Los Angeles California 90033 United States Details
UCHealth University of Colorado Hospital Aurora Colorado 80045 United States Details
Moffitt Cancer Center Tampa Florida 33612 United States Details
NYP/Weill Cornell Medical Center New York New York 10065 United States Details
Ohio State University Comprehensive Cancer Center Columbus Ohio 43210 United States Details
University of Pittsburgh Cancer Institute (UPCI) Pittsburgh Pennsylvania 15232 United States Details
UT Southwestern/Simmons Cancer Center-Dallas Dallas Texas 75390 United States Details
Huntsman Cancer Institute/University of Utah Salt Lake City Utah 84112 United States Details
University Health Network-Princess Margaret Hospital Toronto Ontario M5G 2M9 Canada Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field